UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies

Journal of clinical oncology, 2002-09, Vol.20 (18), p.3906-3927

SCAPPATICCI, Frank A

2002

Volltextzugriff (PDF)

Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial

Journal of clinical oncology, 2011-06, Vol.29 (16), p.2215-2222

2011

Volltextzugriff (PDF)

Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer

Journal of clinical oncology, 2007-10, Vol.25 (29), p.4536-4541

2007

Volltextzugriff (PDF)

Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma

Molecular therapy, 2005-11, Vol.12 (5), p.778-788

2005

Volltextzugriff (PDF)

Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab

JNCI : Journal of the National Cancer Institute, 2007-08, Vol.99 (16), p.1232-1239

2007

Volltextzugriff (PDF)

Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma

Cancer, 2013-01, Vol.119 (2), p.380-387

2013

Volltextzugriff (PDF)

Combination Angiostatin and Endostatin Gene Transfer Induces Synergistic Antiangiogenic Activity in Vitro and Antitumor Efficacy in Leukemia and Solid Tumors in Mice

Molecular therapy, 2001-02, Vol.3 (2), p.186-196

2001

Volltextzugriff (PDF)

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

Journal of surgical oncology, 2005-09, Vol.91 (3), p.173-180

2005

Volltextzugriff (PDF)

Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation

Future oncology (London, England), 2015-01, Vol.11 (1), p.61-71

2015

Volltextzugriff (PDF)

Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2011-08, Vol.6 (8), p.1418-1425

2011

Volltextzugriff (PDF)

Safety and Efficacy of Combining Sunitinib with Bevacizumab + Paclitaxel/Carboplatin in Non-small Cell Lung Cancer

Journal of thoracic oncology, 2010-03, Vol.5 (3), p.354-360

2010

Volltextzugriff (PDF)

Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.402-402

2017

Volltextzugriff (PDF)

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

European journal of cancer (1990), 2011-12, Vol.47 (18), p.2706-2714

2011

Volltextzugriff (PDF)

The therapeutic potential of novel antiangiogenic therapies

Expert opinion on investigational drugs, 2003-06, Vol.12 (6), p.923-932

Scappaticci, Frank A

2003

Volltextzugriff (PDF)

Statin-AE: A novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity

Angiogenesis (London), 2001, Vol.4 (4), p.263-268

2001

Volltextzugriff (PDF)

A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS3620-TPS3620

2018

Volltextzugriff (PDF)

Reply to B.I. Rini et al

Journal of clinical oncology, 2010-06, Vol.28 (17), p.e286-e287

2010

Volltextzugriff (PDF)

P-358 Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2003-08, Vol.41, p.S182-S182

2003

Volltextzugriff (PDF)

MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer

Clinical cancer research, 2019-05, Vol.25 (10), p.2988-2995

2019

Volltextzugriff (PDF)

The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review

Advances in therapy, 2020-07, Vol.37 (7), p.3059-3082

2020

Volltextzugriff (PDF)

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2004-09, Vol.45 (3), p.381-386

2004

Volltextzugriff (PDF)

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)

The oncologist (Dayton, Ohio), 2019-07, Vol.24 (7), p.921-932

2019

Volltextzugriff (PDF)

Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV) vs FOLFOX-BV for first-line (1L) treatment (tx) of patients with metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.657-657

2017

Volltextzugriff (PDF)

Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.492-492

2016

Volltextzugriff (PDF)

Cyclophosphamide metabolite interacts with a 35kd cancer-associated protein

Scappaticci, Frank Anthony

1991

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)
Dissertationen
(1)

Sprache

Englisch
(25)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Humans
(17)
Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Female
(13)
Oncology
(12)
Male
(11)
Middle Aged
(10)
Aged
(9)
Aged, 80 And Over
(8)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Adult
(7)
Tumors
(7)
Animals
(6)
Antineoplastic Agents - Therapeutic Use
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Bevacizumab
(6)
Angiogenesis
(5)
Antibodies, Monoclonal, Humanized
(5)
Lung Neoplasms - Drug Therapy
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies

Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial

Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer

Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma

Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab

Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma

Combination Angiostatin and Endostatin Gene Transfer Induces Synergistic Antiangiogenic Activity in Vitro and Antitumor Efficacy in Leukemia and Solid Tumors in Mice

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation

Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer

Safety and Efficacy of Combining Sunitinib with Bevacizumab + Paclitaxel/Carboplatin in Non-small Cell Lung Cancer

Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

The therapeutic potential of novel antiangiogenic therapies

Statin-AE: A novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity

A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613

Reply to B.I. Rini et al

P-358 Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer

MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer

The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)

Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV) vs FOLFOX-BV for first-line (1L) treatment (tx) of patients with metastatic colorectal cancer (mCRC)

Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC)

Cyclophosphamide metabolite interacts with a 35kd cancer-associated protein

Suchergebnisse filtern